心力衰竭治疗药物的表观遗传药理学进展

doi:10.12092/j.issn.1009-2501.2019.03.018

摘要/Abstract

摘要：

心力衰竭（heart failure，HF）是心室收缩和（或）舒张功能发生障碍的一种疾病，又称心功能不全，可由多种因素引起，主要表现为心脏结构和功能的异常改变，并以交感神经、肾素-血管紧张素-醛固酮等系统激活为特征。通过临床观察，心衰患者在药物治疗期间存在极大异质性，因此在实际用药时，除了要考虑一般的环境因素，还要顾及遗传背景，尤其是序列不改变的表观遗传学。目前，有报道认为心衰患者的用药反应和DNA甲基化、组蛋白修饰、microRNA等修饰相关，但涉及该领域的研究还不多见，因此本文就近几年心衰治疗药物的表观遗传药理学进展进行一个较为全面的综述。

关键词: 心力衰竭, 表观遗传学, DNA甲基化, 组蛋白修饰, 微小RNA

Abstract:

Heart failure (HF) is called cardiac insufficiency and mainly manifested in abnormal changes in cardiac structure and function such as ventricular systolic and (or) diastolic dysfunction, characteristic of sympathetic nerve and renin-angiotensin-aldosterone system activation. Clinical observation has showed that there was great heterogeneity in patients with HF during drug treatment. Therefore, we should take into account not only environmental factors but also genetic ones in terms of drug use, especially the epigenetics. Recently, some reports admited that the drug response of patients with HF was partly related to epigenetic modifications such as DNA methylation, histone modifications and microRNAs. But the relevant research is still rare as yet. Therefore, this article reviews the advances of epigenetic pharmacology in the treatment of HF in recent years.

Key words: heart failure, epigenetics, DNA methylation, histone modification, microRNA

中图分类号:

R541

沈蕾，王柯柯，杨景柯，赵俊涛，孟祥光，袁义强. 心力衰竭治疗药物的表观遗传药理学进展[J]. 中国临床药理学与治疗学, 2019, 24(3): 343-349.

SHEN Lei, WANG Keke, YANG Jingke, ZHAO Juntao, MENG Xiangguang, YUAN Yiqiang. Advances in drugs and genetic pharmacology for heart failure[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 343-349.

参考文献

［1］张健, 张宇辉. 多中心、前瞻性中国心力衰竭注册登记研究—病因、临床特点和治疗情况初步分析［J］. 中国循环杂志,2015, 30(5): 413-416.
［2］Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC［J］. Eur J Heart Fail,2016, 18(8): 891-975.
［3］Mottet F, Vardeny O, de Denus S. Pharmacogenomics of heart failure: a systematic review［J］. Pharmacogenomics, 2016,17(16): 1817-1858.
［4］Kaufman AL, Spitz J, Jacobs M, et al. Evidence for clinical implementation of pharmacogenomics in cardiac drugs［J］. Mayo Clin Proc, 2015,90(6): 716-729.
［5］Iyngkaran P, Thomas MC, Johnson R, et al. Contextualizing genetics for regional heart failure care［J］. Curr Cardiol Rev,2016,12(3): 231-242.
［6］Pepin ME, Ha CM, Crossman DK, et al. Genome-wide DNA methylation encodes cardiac transcriptional reprogramming in human ischemic heart failure［J］. Lab Invest, 2018, 99(3):371-386.
［7］Schiano C, Vietri MT, Grimaldi V, et al. Epigenetic-related therapeutic challenges in cardiovascular disease［J］.Trends Pharmacol Sci,2015,36(4): 226-35.
［8］Veland N, Lu Y, Hardikar S, et al. DNMT3L facilitates DNA methylation partly by maintaining DNMT3A stability in mouse embryonic stem cells［J］.Nucleic Acids Res, 2018, 47(1):152-167.
［9］Napoli C, Grimaldi V, De Pascale MR, et al. Novel epigenetic-based therapies useful in cardiovascular medicine［J］. World J Cardiol,2016, 8(2): 211-219.
［10］Wu LX, Wen CJ, Li Y, et al. Interindividual epigenetic variation in ABCB1 promoter and its relationship with ABCB1 expression and function in healthy Chinese subjects［J］. Br J Clin Pharmacol,2015,80(5): 1109-1121.
［11］Thome JG, Mendoza MR, Cheuiche AV, et al. Circulating microRNAs in obese and lean heart failure patients: A case-control study with computational target prediction analysis［J］. Gene，2015， 574(1):1-10.
［12］Gonzalez-Fierro A, Vasquez-Bahena D, Taja-Chayeb L, et al. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype［J］. Int J Clin Pharmacol Ther, 2011,49(8): 519-524.
［13］Sabia C, Picascia A, Grimaldi V, et al.The epigenetic promise to improve prognosis of heart failure and heart transplantation［J］. Transplant Rev (Orlando),2017,31(4): 249-56.
［14］Yerra VG, Advani A. Histones and heart failure in diabetes［J］. Cell Mol Life Sci, 2018, 75(17):3193-3213.
［15］Reddy MA, Sumanth P, Lanting L, et al. Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice［J］.Kidney Int，2014，85(2): 362-373.
［16］Sunagawa Y, Funamoto M, Sono S, et al.Curcumin and its demethoxy derivatives possess p300 HAT inhibitory activity and suppress hypertrophic responses in cardiomyocytes［J］. J Pharmacol Sci,2018,136(4): 212-217.
［17］Ghosh AK, Rai R, Flevaris P, et al.Epigenetics in Reactive and Reparative Cardiac Fibrogenesis: The Promise of Epigenetic Therapy［J］.J Cell Physiol，2017，232(8): 1941-1956.
［18］曾振华, 刘建新, 曹春芽, 等. 硝酸甘油耐受大鼠主动脉差异microRNA筛选与生物信息学分析［J］. 中国临床药理学与治疗学，2018，23(10): 1081-1087.
［19］Tounsi N, Trabelsi I, Kerkeni E, et al. ABCB1 and SLCO1B3 gene polymorphisms and their impact on digoxin pharmacokinetics in atrial fibrillation patients among the tunisian population［J］. Pharmacology，2017，99(5/6):250-258.
［20］Kadokura T, Groenendaal D, Heeringa M, et al. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin［J］.Eur J Drug Metab Pharmacokinet,2014,39(1): 1-9.
［21］付孟龙, 周宏灏. MDR1基因多态性及其临床相关性［J］.中国临床药理学与治疗学, 2016, 21(4): 463-469.
［22］Jiang Z, Wei C, Sun Z, et al. A simple and sensitive gas chromatography method for determination of isosorbide dinitrate and its metabolites in human plasma: application to pharmacokinetics study on oral spray［J］. Drug Res (Stuttg), 2014, 64(2): 73-78.
［23］Xu J, Huang Z, Lin L, et al. miRNA-130b is required for the ERK/FOXM1 pathway activation-mediated protective effects of isosorbide dinitrate against mesenchymal stem cell senescence induced by high glucose［J］.Int J Mol Med, 2015, 35(1): 59-71.
［24］Kao YH, Cheng CC, Chen YC, et al. Hydralazine-induced promoter demethylation enhances sarcoplasmic reticulum Ca2+-ATPase and calcium homeostasis in cardiac myocytes［J］. Lab Invest,2011,91(9): 1291-1297.
［25］Benge CD, Muldowney JA, 3rd. The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population［J］. Expert Opin Drug Metab Toxicol, 2012, 8(11): 1469-1482.
［26］Kadakol A, Malek V, Goru SK, et al.Telmisartan and esculetin combination ameliorates type 2 diabetic cardiomyopathy by reversal of H3, H2A, and H2B histone modifications［J］. Indian J Pharmacol,2017,49(5): 348-56.
［27］King AD, Huang K, Rubbi L, et al. Reversible Regulation of Promoter and Enhancer Histone Landscape by DNA Methylation in Mouse Embryonic Stem Cells［J］. Cell Rep, 2016, 17(1): 289-302.
［28］Zhu X, Li Q, Chang R, et al. Curcumin alleviates neuropathic pain by inhibiting p300/CBP histone acetyltransferase activity-regulated expression of BDNF and cox-2 in a rat model［J］. PLoS One,2014,9(3): e91303.
［29］Jankun J, Wyganowska-Swiatkowska M, Dettlaff K, et al.Determining whether curcumin degradation/condensation is actually bioactivation (Review) ［J］. Int J Mol Med, 2016,37(5): 1151-1158.
［30］Rahman AF, Angawi RF, Kadi AA. Spatial localisation of curcumin and rapid screening of the chemical compositions of turmeric rhizomes (Curcuma longa Linn.) using Direct Analysis in Real Time-Mass Spectrometry (DART-MS) ［J］. Food Chem, 2015, 173: 489-494.
［31］Cao Q, Zhang J, Gao L, et al.Dickkopf3 upregulation mediates the cardioprotective effects of curcumin on chronic heart failure［J］. Mol Med Rep, 2018, 17(5): 7249-7257.
［32］Parker BM, Rogers SL, Lymperopoulos A. Clinical pharmacogenomics of carvedilol: the stereo-selective metabolism angle［J］.Pharmacogenomics,2018,19(14): 1089-1093.
［33］Nikolic VN, Jankovic SM, Deljanin-Ilic M, et al. Population pharmacokinetic analysis of bisoprolol in patients with stable coronary artery disease［J］. Eur J Drug Metab Pharmacokinet,2018,43(1): 35-44.
［34］Sucharov CC, Kao DP, Port JD, et al. Myocardial microRNAs associated with reverse remodeling in human heart failure［J］.JCI Insight,2017, 2(2): e89169.
［35］Kim IM, Wang Y, Park KM, et al. beta-arrestin1-biased beta1-adrenergic receptor signaling regulates microRNA processing［J］. Circ Res,2014,114(5): 833-844.
［36］Teoh JP, Bayoumi AS, Aonuma T, et al. beta-arrestin-biased agonism of beta-adrenergic receptor regulates Dicer-mediated microRNA maturation to promote cardioprotective signaling［J］. J Mol Cell Cardiol, 2018, 118: 225-236.
［37］Tomaniak M, Sygitowicz G, Blaszczyk O, et al. miR-1, miR-21, and galectin-3 in hypertensive patients with symptomatic heart failure and left ventricular hypertrophy［J］. Kardiol Pol, 2018,76(6): 1009-1011.
［38］Yu HD, Xia S, Zha CQ, et al. Spironolactone regulates HCN protein expression through micro-rna-1 in rats with myocardial infarction［J］. J Cardiovasc Pharmacol,2015,65(6): 587-592.
［39］Luo S, Chen Y, He R, et al. Rescuing infusion of miRNA-1 prevents cardiac remodeling in a heart-selective miRNA deficient mouse［J］. Biochem Biophys Res Commun,2018, 495(1): 607-613.
［40］Li X, Zhang X, Wang T, et al. Regulation by bisoprolol for cardiac microRNA expression in a rat volume-overload heart failure model［J］. J Nanosci Nanotechnol, 2013, 13(8): 5267-5275.
［41］Brater DC. Update in diuretic therapy: clinical pharmacology［J］.Semin Nephrol,2011,31(6): 483-494.
［42］Stillitano F, Lonardo G, Zicha S, et al. Molecular basis of funny current (If) in normal and failing human heart［J］. J Mol Cell Cardiol,2008, 45(2): 289-299.
［43］Yang L, Wang B, Zhou Q, et al. MicroRNA-21 prevents excessive inflammation and cardiac dysfunction after myocardial infarction through targeting KBTBD7［J］.Cell Death Dis, 2018, 9(7): 769.
［44］Chimenti I, Pagano F, Cavarretta E, et al. Beta-blockers treatment of cardiac surgery patients enhances isolation and improves phenotype of cardiosphere-derived cells［J］. Sci Rep, 2016, 6: 36774.
［45］Adam O, Zimmer C, Hanke N, et al. Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice［J］. J Mol Cell Cardiol,2015, 85: 140-150.
［46］鲁秀玲, 高玉梅, 赵志刚. 血管紧张素转换酶抑制剂的研究与临床应用［J］. 药品评价,2010, 7(24): 29+32-5+9.
［47］Rana I, Velkoska E, Patel SK, et al.MicroRNAs mediate the cardioprotective effect of angiotensin-converting enzyme inhibition in acute kidney injury［J］. Am J Physiol Renal Physiol,2015,309(11): F943-954.
［48］Satoh M, Takahashi Y, Tabuchi T, et al. Circulating Toll-like receptor 4-responsive microRNA panel in patients with coronary artery disease: results from prospective and randomized study of treatment with renin-angiotensin system blockade［J］. Clin Sci (Lond),2015,128(8): 483-491.
［49] Rawal S, Manning P, Katare R. Cardiovascular microRNAs: as modulators and diagnostic biomarkers of diabetic heart disease［J］. Cardiovasc Diabetol,2014, 13: 44.
［50］Morine KJ, Qiao X, York S, et al. Bone Morphogenetic Protein 9 Reduces Cardiac Fibrosis and Improves Cardiac Function in Heart Failure［J］.Circulation, 2018,138(5):513-526.
［51］Kapur NK, Qiao X, Paruchuri V, et al. Reducing endoglin activity limits calcineurin and TRPC-6 expression and improves survival in a mouse model of right ventricular pressure overload［J］.J Am Heart Assoc,2014, 3(4).
［52］Shyu KG, Wang BW, Cheng WP, et al. MicroRNA-208a Increases Myocardial Endoglin Expression and Myocardial Fibrosis in Acute Myocardial Infarction［J］.Can J Cardiol, 2015, 31(5): 679-690.
［53］Rieger JK, Reutter S, Hofmann U, et al. Inflammation-associated microRNA-130b down-regulates cytochrome P450 activities and directly targets CYP2C9［J］. Drug Metab Dispos,2015, 43(6):884-888.

[1]	郝潇, 赵美, 王文静, 张飞飞, 刘惠良, 党懿, 李树仁, 齐晓勇. 钠-葡萄糖共转运体2抑制剂在急性心肌梗死应用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 824-831.
[2]	彭勇, 范剑峰, 熊旭华, 肖冬平, 高招波, 郑春华. 右旋糖酐铁片对合并铁缺乏的射血分数减低的心力衰竭患者的影响[J]. 中国临床药理学与治疗学, 2023, 28(2): 178-183.
[3]	陈玉林, 蒋虎刚, 王新强, 刘凯, 李应东, 安涛, 赵信科. 基于网络药理学和分子对接探讨芪参益心颗粒治疗射血分数保留型心力衰竭的作用机制[J]. 中国临床药理学与治疗学, 2023, 28(10): 1081-1092.
[4]	杨胜, 王德国. 沙库巴曲缬沙坦联合达格列净治疗射血分数减低型心力衰竭疗效及对血清cTnⅠ、BNP水平的影响[J]. 中国临床药理学与治疗学, 2022, 27(9): 1010-1015.
[5]	彭娟, 范琳琳, 李然宜, 李晓宇, 吕迁洲, 邹云增. 心力衰竭药物治疗的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 373-381.
[6]	刘平, 邱博, 吴惠珍. 维利西呱治疗心力衰竭的药理作用与临床评价[J]. 中国临床药理学与治疗学, 2022, 27(2): 212-218.
[7]	岳玲, 杜俊宏, 刘晓, 李玉兰, 许飞雪. 组蛋白甲基化及乙酰化修饰酶在卵巢癌中的机制研究及治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(11): 1299-1306.
[8]	徐永华, 施向红. 托拉塞米联合左卡尼汀治疗慢性心力衰竭的疗效分析[J]. 中国临床药理学与治疗学, 2021, 26(6): 647-652.
[9]	彭福生, 黄小惠, 李鹏, 汤建儿. miR-34a通过调控雄激素受体基因抑制前列腺癌细胞系LNCaP增殖[J]. 中国临床药理学与治疗学, 2021, 26(1): 10-17.
[10]	陈力方, 王博, 王维蓉. 组蛋白去乙酰化酶3在心血管疾病中的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(1): 88-97.
[11]	范剑峰，方译，郑春华. 沙库巴曲缬沙坦钠治疗慢性心力衰竭患者的临床疗效分析[J]. 中国临床药理学与治疗学, 2019, 24(7): 810-814.
[12]	朱林佳，原少斐，上官宗校，慈晓，赵仁国，李玉苹. 超声-微泡介导的microRNA-449a通过调节Notch1对肺癌细胞的生长抑制作用[J]. 中国临床药理学与治疗学, 2019, 24(12): 1385-1393.
[13]	吴娟, 吴勇军, 李智, 曾长, 李振丰, 唐仪, 卢淼, 张雪纯, 张万勇, 王丹慧, 刘晨睿. 肿瘤中Dapper蛋白家族表观遗传调控的研究进展[J]. 中国临床药理学与治疗学, 2019, 24(12): 1434-1440.
[14]	韩晨阳，杨毅，李文燕，王瑾，郭丽. MicroRNA-136靶向CD163抑制CD68⁺CD163⁺M2型巨噬细胞极化的作用研究[J]. 中国临床药理学与治疗学, 2019, 24(1): 1-8.
[15]	魏子寒，李栋博，元峥，陆颍，杨国杰. 沙库巴曲缬沙坦治疗左心疾病相关性肺动脉高压的临床研究[J]. 中国临床药理学与治疗学, 2019, 24(1): 57-62.